Тримедат Валента

Quick links

Choose a section

Quick links to important sections

Advertisements

Тримедат Валента

Advertisements
Advertisements

Overview of Тримедат Валента

What is Тримедат Валента? (Trimebutine)

Property Description
Active ingredient Trimebutine
Form Film-coated tablets, Injectable solution
Pharmacological class Gastrointestinal motility regulator
General purpose Normalizes bowel movement and reduces visceral sensitivity
Origin Synthetic (Small molecule drug)

Classification and Core Identity

Тримедат Валента is a specific Russian brand name for a synthetic medicinal product whose active ingredient is Trimebutine, typically formulated as the maleate salt. Its function is identified as an agent that normalizes the body's internal gut rhythms. It is primarily classified as a gastrointestinal motility regulator and a spasmolytic agent. Its core role is to restore the essential, coordinated motor function of the intestines and colon, addressing the underlying mechanical dysfunctions in the gut.


Compositional Form and Mechanism

The active substance, Trimebutine maleate, is a single-ingredient product of synthetic origin. This agent is available in several standard pharmaceutical preparations, including common film-coated tablets for oral intake and an injectable solution for parenteral administration. This dual availability gives it flexibility in addressing varying states of digestive distress.

The mechanism is characterized by its dual action on the digestive tract: the compound can simultaneously stimulate sluggish muscle movement (hypomotility) and calm excessive spasms (hypermotility). This comprehensive regulatory effect is achieved by interacting with peripheral mu, kappa, and delta opioid receptors in the bowel wall. This unique, triple-receptor action is a defining feature that enables it to provide balanced control over both the movement and the visceral sensation of the lower gastrointestinal tract.

Advertisements

What side effects are possible with Тримедат Валента?

Official Safety Profile and Adverse Reactions

The safety profile of Trimebutine maleate, the active ingredient in Тримедат Валента, is classified by regulatory authorities based on the frequency and system affected, as documented in official prescribing information.

Adverse Reactions by System and Frequency

Adverse reactions are officially grouped into System-Organ Classes (SOCs) and classified by frequency into categories such as Common, Uncommon, and Not Known.

Common adverse reactions, reported across regulatory documents, primarily affect the Gastrointestinal and Nervous Systems. These commonly listed effects include dry mouth, constipation, diarrhea, dizziness, headache, and drowsiness.

Uncommon reactions may include a rash. Other reactions, classified as Not Known (frequency cannot be estimated from available data), include various hypersensitivity reactions, such as severe skin reactions like Erythema multiforme and Toxic skin eruption.

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions have been documented, particularly during post-marketing surveillance or in cases of overdose. These include reports of liver dysfunction and jaundice. Overdose reports have also documented significant cardiac (e.g., QTc interval prolongation, bradycardia, tachycardia) and neurological events (e.g., convulsions, coma).

Population-Specific Safety Constraints are explicitly stated in official labeling. The drug is not recommended for use in children under 12 years of age in some documents and is contraindicated in children under 2 years in others. Use during pregnancy is generally not recommended due to limited adequate data. Furthermore, the tablet formulation contains lactose, leading to a regulatory constraint for individuals with certain hereditary metabolic disorders like lactase deficiency or galactose intolerance.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Trimebutine maleate outlines specific clinical manifestations and mandated actions in the event of overexposure. Overdose manifestations are documented to affect the Central Nervous System (CNS), potentially resulting in neurological disorders such as drowsiness, convulsions, loss of consciousness, and coma.

Cardiovascular effects are also documented, including bradycardia, tachycardia, prolongation of the QTc interval, and ventricular tachycardia. Arterial hypertension has also been reported. These severe manifestations underscore the necessity for immediate external intervention. Cases of serious overdose have been reported in both infants and young adults.

Seeking Emergency Medical Care:

Regulatory guidance mandates that individuals seek immediate medical attention upon suspicion of overdose. It is required to contact a regional poison control centre or emergency services if severe symptoms—such as passing out, trouble breathing, or having a seizure—occur.

Management and Monitoring:

The documented management strategy is limited to symptomatic and supportive treatment, as no specific antidote is known to be available. Following oral overexposure, gastric lavage may be recommended as a procedural measure. Due to the risk of severe cardiac and neurological outcomes, supervision in a specialized monitoring environment is essential.

Advertisements

Therapeutic Uses of Тримедат Валента

Quick Facts

  • Irritable Bowel Syndrome (IBS): May offer relief for symptoms such as abdominal pain, cramping, bloating, and changes in bowel habits.
  • Functional Digestive Disorders: May be used to manage polymorphous symptoms related to general gastrointestinal dysfunction.
  • Post-operative Ileus: May help in restoring movement of the intestinal tract following certain abdominal surgical procedures.

Тримедат Валента (Trimebutine maleate) is a prescribed medication used to address conditions involving irregular movement and discomfort in the digestive tract. The primary therapeutic focus is on the symptomatic management of Irritable Bowel Syndrome (IBS). For individuals diagnosed with IBS, this drug may help to reduce the frequency and severity of symptoms like abdominal pain, cramping, intestinal spasms, and discomfort. It is also indicated for managing various other functional digestive disorders that present with general gastrointestinal distress.

Additionally, this drug is an option for use in a hospital setting to help initiate the return of normal gut movement following specific types of abdominal surgery, a condition known as post-operative paralytic ileus. The therapeutic objective is to help normalize the intestinal tract's rhythm.

Advertisements

Eligibility and Restrictions for Use

Eligibility for Use

Official regulatory documents define strict criteria for the use of Trimebutine maleate (Тримедат Валента), focusing solely on population eligibility and non-eligibility.

Populations Contraindicated (Must Not Use)

Category Restriction Status
Hypersensitivity Contraindicated in patients with known allergy to Trimebutine maleate or any excipients.
Age Restriction Contraindicated in children under 2 years of age (though specific minimum ages vary by formulation and regulatory region).
Pregnancy Contraindicated or strongly advised against during the first trimester.

Populations with Restricted or Conditional Use

Category Restriction Status
Lactation Not recommended; safety has not been established. Breastfeeding should be discontinued if treatment is necessary.
Pediatric Use Not recommended for children under 12 years for many standard adult-strength formulations.
Metabolic Disorders Not recommended for patients with metabolic disorders, such as lactose intolerance, due to tablet excipients.

Eligibility for use is primarily established for adults and adolescents over 12 years of age, subject to the explicit contraindications and restrictions defined by national health authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Trimebutine maleate (Тримедат Валента) as described in authoritative government regulatory documents.

Documented Pharmacodynamic Interactions

The primary documented interaction involves neuromuscular blocking agents. Official product monographs note that co-administration of Trimebutine maleate has been shown to increase the duration of curarization induced by substances such as d-tubocurarine. This represents a pharmacodynamic potentiation effect that is clinically significant in settings where such agents are used.

Absence of Documented Pharmacokinetic Restrictions

Official regulatory information does not formally specify restrictions or required monitoring related to pharmacokinetic mechanisms, such as those involving CYP-mediated liver enzymes or drug transporters. This indicates a limited scope of documented metabolic interactions.

Regulatory Constraints and Classifications

Interaction Constraint Official Regulatory Status
Contraindicated Combinations None formally specified in regulatory documents.
Timing Separation Rules No mandatory administration timing rules are specified.
Food or Alcohol Interactions No formal restrictions or interaction patterns specified with food or alcohol.

The official interaction profile is defined by the specific caution regarding the potentiation of neuromuscular blockade effects. Otherwise, regulatory documents do not detail mandatory dose spacing or broader constraints based on metabolic pathways.

Advertisements

Mechanism of Action

How Тримедат Валента Works

Modulation of Enteric Nerve Signaling

The drug's active substance functions as a full agonist, binding to and activating peripheral mu (mu), delta (delta), and kappa (kappa) opioid receptors primarily located within the Enteric Nervous System (ENS) of the gastrointestinal tract. This interaction modulates the transmission of nerve signals that govern local gut movement and sensation, influencing signaling dynamics within the enteric system.


Dual Regulatory Effect on Muscle Activity

The mechanism acts as a dual regulator, influencing both diminished and excessive contractile activity across the gut. It targets the regulatory pathways to either stimulate weak contractions or modulate excessive spasms, influencing the propagation of the Migrating Motor Complex (MMC) along the entire gastrointestinal tract.


Influence on Ion Channels

This regulation is further supported by the active substance's influence on smooth muscle cell electrophysiology. It modulates the flow of ions, specifically calcium (Ca^2+) and potassium (K^+), across the muscle cell membranes. This electrophysiological control stabilizes muscle cell excitability and regulates spontaneous electrical discharge, contributing to coordinated motor patterns.

Advertisements

Dosage and Administration Information

Administration Scope

Usage Parameter General Administration Details
Route of Administration The medication is supplied for Oral intake (tablets) and for Parenteral administration (injectable solution) in clinical settings.
Standard Dosing Schedule The adult recommended daily dose is typically up to 600 mg in divided doses. This is commonly administered as one 200 mg tablet three times daily.
Timing in Relation to Meals Oral administration is generally scheduled to occur before meals.
Missed-Dose Rules If a dose is missed, the recommended approach is to skip the forgotten dose and continue with the next regularly scheduled dose. Doses should not be doubled to compensate for a missed dose.
Age-Group Rules The tablet formulations (100 mg and 200 mg) are primarily for adult use; pediatric applications involve specific weight-based dosing and medical supervision.

Instruction Classifications (High-level)

Classification Type Description
Administration Method Oral or Parenteral (Intramuscular/Intravenous).
Frequency Pattern Typically three times daily for immediate-release forms.
Use-Context Constraints Injectable use is for supervised clinical or hospital settings for acute treatment; oral use is for outpatient administration.

Connection to the Overall Use Protocol

There is a procedural distinction between the oral regimen for standard use and the parenteral route reserved for acute, supervised care. The standardized maximum daily dose, divided into a three-times-daily schedule taken before meals, establishes the high-level framework for consistent administration. These parameters form the core structure for the use of the product.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Тримедат Валента

Evidence for use in Irritable Bowel Syndrome (IBS) and Functional Digestive Disorders

Research regarding Trimebutine has primarily involved analyzing data from randomized controlled trials (RCTs) and systematic reviews, which are study designs used in research exploring how symptoms change over time. These studies have focused on adult populations experiencing the fluctuating or episodic manifestations of Irritable Bowel Syndrome (IBS) and other functional gastrointestinal conditions. Researchers specifically measured potential changes in outcomes related to physical discomfort, such as the intensity and frequency of abdominal pain and cramping.

Studies monitored how symptoms were described in the observed populations during short-term study periods, often lasting between two and six weeks. Findings describe patterns observed in the studies, including measurements related to global measures of IBS symptom assessment and patient-reported outcomes describing perceived discomfort. The evidence base includes systematic reviews and meta-analyses synthesizing these short-term findings.

Evidence for use in Post-operative Paralytic Ileus (POI)

Trimebutine was also evaluated in research scenarios focusing on post-operative care, specifically in conditions associated with acute episodes such as Post-operative Paralytic Ileus (POI). These studies were often short-term RCTs involving adult patients recovering from surgery. The research examined physiological outcomes related to systemic or functional imbalance by monitoring the time required to achieve certain functional milestones. Studies monitored the recorded time until the first passage of gas (flatus) and the time until the first bowel movement after surgery.

What is still uncertain about Тримедат Валента research

The duration of observation in most high-quality studies for IBS and functional disorders was limited to the short term. This means that long-term effects remain to be established. Research focused on episodes where symptoms become more noticeable, and the follow-up durations were typically limited to weeks. Evidence for the sustained management of symptoms over extended periods remains limited. Additionally, data for certain groups, such as children and adolescents, remain insufficient, and research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

  1. Trimebutine Maleate and Pinaverium Bromide for Irritable Bowel Syndrome: A Review of the Clinical Effectiveness, Safety and Guidelines
  2. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Тримедат Валента (FAQ)

Q: What is Тримедат Валента?

A: Тримедат Валента (Trimebutine maleate) is a medication classified as an antispasmodic that acts on the smooth muscle of the gastrointestinal tract. It is used to help regulate the movement (motility) of the gut. It is sometimes described as a motility regulator or a gastrointestinal prokinetic agent.


Q: What is the active ingredient in Тримедат Валента?

A: The active ingredient in the medication is trimebutine maleate.


Q: What is trimebutine maleate used for?

A: Trimebutine maleate is used to help treat symptoms related to certain disorders of the gastrointestinal tract, such as the Irritable Bowel Syndrome (IBS). It is intended to relieve symptoms like abdominal pain, cramps, bloating, and irregular bowel movements (diarrhea or constipation) associated with these conditions.


Q: How does Тримедат Валента work?

A: Trimebutine maleate works by acting on opioid receptors in the gut. This action helps to regulate the muscular activity (peristalsis) of the intestinal wall, either stimulating movement when the gut is too slow or slowing it down when it is too fast. This allows it to normalize the overall rhythm of the digestive system.


Q: Who can take Тримедат Валента?

A: This medication is typically prescribed for adults and adolescents suffering from functional bowel disorders like IBS. It is not generally intended for children under 3 years old. A healthcare provider determines if this medication is appropriate based on an individual's specific symptoms and medical history.


Q: What are common side effects of trimebutine maleate?

A: Common side effects are generally mild and temporary. They may include:

  • Dry mouth
  • Nausea
  • Constipation or diarrhea
  • Fatigue or drowsiness
  • Headache

If any side effects are severe or persistent, it is important to consult a healthcare provider.


Q: Should I take Тримедат Валента with food?

A: The medication can generally be taken before, during, or after a meal. The specific timing, as well as the exact dosage, should be followed exactly as instructed by the prescribing healthcare provider or according to the patient information leaflet.


Q: What should I do if I miss a dose?

A: If a dose is missed, it should be taken as soon as it is remembered, unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Do not take a double dose to make up for a missed one.


Q: Is it safe to drink alcohol while taking Тримедат Валента?

A: While there are no known major interactions between trimebutine maleate and alcohol, it is generally advisable to limit alcohol intake when taking any medication. Alcohol can potentially worsen gastrointestinal symptoms or increase the risk of certain side effects like drowsiness. Consult a healthcare provider regarding alcohol use.


Q: Can Тримедат Валента be taken during pregnancy or breastfeeding?

A: The safety of trimebutine maleate during pregnancy and breastfeeding has not been definitively established. It is not generally recommended unless a healthcare provider determines that the potential benefit outweighs the potential risk. A medical professional must be consulted before using this medication if you are pregnant, planning to become pregnant, or breastfeeding.

Advertisements

How should Тримедат Валента be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal instructions for Тримедат Валента (Trimebutine maleate) are defined by regulatory documents to ensure the product's stability and safety.

Requirement Type Official Condition
Maximum Temperature Store at a temperature not exceeding 30 C
Child Safety Keep out of the reach and sight of children
Packaging Rule Store the tablets in their original blister and outer carton
Stability Limit Do not use the medicine after the labeled expiry date
Disposal Dispose of unused or expired product according to local regulatory guidelines for pharmaceutical waste

Storage must adhere to the 30 C temperature maximum to preserve the integrity of the medication until the printed expiry date. Used or expired medication must be discarded responsibly in compliance with established local pharmaceutical waste procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тримедат Валента found in:

A-Z Index: